LSD Microdose: Effects, Science, and Potential Risks

LSD microdosing typically involves taking roughly one-tenth to one-twentieth of a full psychedelic dose, usually somewhere between 5 and 26 micrograms, with the aim of gaining subtle cognitive or emotional benefits without hallucinating. The practice has attracted enormous popular interest and a growing body of controlled research, but the science so far tells a complicated story. Some biological effects are real and measurable. Whether those effects translate into the life-changing benefits that microdosing enthusiasts describe remains genuinely uncertain, with placebo and expectancy effects looming large over nearly every positive finding.

What Counts as a Microdose

There is no single official definition of a microdose, but researchers generally study doses between 5 and 26 micrograms of LSD. A typical full psychedelic dose is around 100 to 200 micrograms, so microdoses represent a fraction of what would produce vivid hallucinations. In controlled trials, doses of 13 and 26 micrograms produce measurable subjective effects: participants reliably report “feeling a drug effect,” and the higher end of that range can increase feelings of vigor and stimulation.¹ At 5 or 10 micrograms, the subjective experience is often indistinguishable from placebo, which is itself a revealing data point.

Most microdosing protocols involve taking a dose every three to four days rather than daily. This spacing partly reflects how quickly tolerance develops to LSD’s effects on serotonin receptors. In one study that administered four repeated doses at three- to four-day intervals, the 26-microgram dose continued to produce modest subjective effects across sessions without obvious tolerance buildup on the drug-effect measures, though it still did not improve mood or cognitive performance compared to placebo.²

What People Report Feeling

The subjective landscape of microdosing is where popular accounts and laboratory data begin to diverge. At doses of 5 and 20 micrograms, placebo-controlled research has found increases in positive mood, friendliness, and arousal, along with fewer attentional lapses. But the same doses also increased confusion and anxiety in some participants.³ The profile is not uniformly positive, even at these tiny doses. People tend to remember and report the pleasant effects, which helps explain the gap between anecdotal enthusiasm and what the data actually show.

In an open-label depression trial, participants described their experiences in strikingly positive terms: improved mood, reduced sadness, and a sense that the changes were “life-changing.”⁴ These accounts are genuine, but they come from a study where everyone knew they were receiving LSD, which makes it impossible to separate the drug’s pharmacological action from the powerful psychological effects of expecting a novel, promising treatment.

Biological Changes That Are Measurable

Even if the subjective benefits are hard to pin down, microdoses of LSD do produce detectable changes in the body and brain. One of the most discussed findings involves BDNF, a protein that supports the growth and maintenance of neurons. In healthy volunteers, doses of 5 and 20 micrograms significantly increased BDNF levels in blood plasma for up to six hours after administration.⁵ The 10-microgram dose, curiously, did not produce a significant change, suggesting the dose-response relationship is not a simple straight line.

The BDNF finding has attracted interest because it raises the possibility that microdoses could promote neuroplasticity, the brain’s ability to rewire itself. A review of psychedelic neuroplasticity research noted that while sub-hallucinogenic doses showed short-term BDNF increases, studies using higher doses produced inconsistent results, with some failing to find any change even at full psychedelic doses.⁶ The prospect of a non-hallucinogenic dose that could enhance brain plasticity is genuinely exciting for conditions like stroke recovery or neurodegeneration, but the evidence so far is preliminary and limited to short-term blood markers. Nobody has yet shown that microdosing actually rewires neural circuits in humans.

Brain imaging offers another window. A small study found that a low dose of LSD altered how the amygdala, a brain region involved in emotional processing, communicates with other areas. Connectivity increased with parts of the frontal cortex and cerebellum but decreased with sensory processing regions.⁷ Whether these changes in connectivity explain any subjective benefits, or are simply the brain responding to a serotonergic drug without downstream consequences, remains an open question.

Depression Trials and What They Actually Show

Depression is perhaps the most closely watched clinical target for microdosing. An open-label trial found that depression scores on a standard clinical scale dropped by about 60% by the end of the intervention period, with improvements sustained for up to six months. Anxiety, rumination, stress, and quality of life all improved as well.⁸ On its face, this is a dramatic result. But open-label trials, where participants know they are receiving the active drug, consistently produce larger effects than blinded trials across all of psychiatry, not just psychedelic research.

A Phase 2a trial that included daily mood tracking found that participants receiving LSD reported feeling happier and more creative on dosing days specifically, but their overall depression scores did not separate from what would be expected without the drug.⁹ That pattern, where people feel something acutely on the day they dose but do not show cumulative improvement in depression overall, is consistent with a drug that has real pharmacological activity but may not produce the lasting therapeutic changes that microdosing advocates hope for. Larger, fully blinded trials will be necessary before any firm conclusions can be drawn.

Where Microdosing Has Fallen Short

The most rigorous test of LSD microdosing to date may be a randomized trial for ADHD in adults. In that study, both the LSD group and the placebo group improved on ADHD symptom scores by similar amounts, with no significant difference between them. The researchers concluded that while repeated low-dose LSD was safe in an outpatient setting, it failed to demonstrate efficacy for ADHD symptoms.¹⁰ A companion study examining whether microdosing improved the cognitive deficits associated with ADHD, such as working memory and attention, found essentially no benefit across multiple neuropsychological tasks. The only effect that reached significance was on a single time-reproduction measure, which the authors themselves flagged as requiring cautious interpretation.¹¹

Creativity is another area where popular claims outrun the evidence. A study using multiple standardized creativity assessments, including tasks measuring divergent thinking, problem-solving, and idea generation, found no effect of LSD microdosing on any measure, either acutely or after sustained dosing.¹² The idea that microdosing unlocks creative potential is one of the practice’s most persistent selling points, and the controlled data simply do not support it.

The Placebo Problem

Psychedelics create an unusual challenge for placebo-controlled research. Even at microdoses, many participants can feel that they have taken an active drug, which breaks the “blind” that clinical trials depend on to separate real drug effects from expectancy. A rapid review of microdosing studies found that the evidence on whether expectancy drives the reported benefits is genuinely mixed. The strongest case for a placebo explanation came from studies showing that participants who correctly guessed they had received a microdose reported much larger effects than those who stayed blinded, and that a participant’s guess about their condition predicted outcomes more than whether they had actually taken the drug.¹³ The same review noted, however, that some of those key studies used doses that may have been too low for pharmacological effects, complicating interpretation.

A computational modeling study took this further, introducing the concept of “activated expectancy bias.” When blinding is imperfect and participants generally expect a positive outcome, the people who correctly guess they are on the active drug get a double boost: the drug effect plus an amplified placebo effect. This uneven distribution of expectancy can inflate treatment effects and generate false positives. When the researchers applied a correction method to a large self-blinding microdose dataset, the apparent differences between microdose and placebo became vulnerable to this bias, leading them to argue that microdosing could function as an “active placebo.”¹⁴ This does not prove that every benefit of microdosing is imaginary. It does mean that the bar for establishing efficacy is higher than in most drug research, because the usual safeguard of blinding is harder to maintain.

Physical Effects on the Body

LSD, even at microdoses, is not pharmacologically inert. The most consistent physiological finding is a modest, temporary increase in blood pressure. In one study, 26 micrograms raised systolic blood pressure from about 105 to 115 mmHg and also increased diastolic pressure, while 13 micrograms raised systolic pressure but had less effect on diastolic readings.¹ A systematic review of microdosing side effects confirmed that these blood pressure elevations are generally small, short-lived, and wear off within a few hours.¹⁵ For a healthy person, a bump of a few mmHg that resolves in hours is unlikely to be clinically significant. For someone with uncontrolled hypertension or a heart condition, even transient spikes could matter.

Sleep is affected in a surprising way. A study using wrist-worn accelerometers across thousands of nights found that participants who microdosed LSD slept about 24 extra minutes the night after dosing, compared to placebo. They went to bed roughly 25 minutes earlier that night, without waking up any later. Sleep on the dosing night itself was unchanged, and the proportion of time in different sleep stages stayed the same, except for a small increase in REM sleep the following night.¹⁶ Whether this represents a beneficial effect or simply a delayed pharmacological rebound is unclear, but it is one of the more cleanly measured physiological changes in the microdosing literature.

Pain is another area of early investigation. An initial small study found that 20 micrograms of LSD increased pain tolerance and decreased the perceived painfulness and unpleasantness of a cold-water test.¹⁷ A later, more detailed study at 15 micrograms found no analgesic effect in the full sample; only in a subset of participants who did not already show ceiling-level pain tolerance at baseline did a signal for increased tolerance emerge, and even then only after the first dose.¹⁸ The evidence for microdosing as a pain treatment is thin and dose-dependent at best.

Time Perception and What It Reveals

One of the more peculiar findings in microdosing research involves the perception of time. At doses as low as 10 micrograms, participants reliably overestimated the duration of time intervals lasting two seconds or longer, essentially perceiving time as passing more slowly than it actually was.¹⁹ A follow-up analysis suggested that this effect was not simply LSD making the clock tick differently in the brain; rather, microdosing appeared to reduce the influence of recently experienced time intervals on subsequent judgments. In other words, each moment was being evaluated more on its own terms, with less anchoring to what came just before.²⁰ This is interesting from a neuroscience perspective because it touches on how the brain builds predictions, but it has no obvious practical application for the average person considering microdosing.

The Cardiac Safety Question

The safety concern that receives the most serious attention from researchers is not about the brain at all but about the heart. LSD and other classic psychedelics bind to the serotonin 5-HT2B receptor, and chronic activation of that receptor has been linked to heart valve damage. Older drugs that strongly stimulated 5-HT2B, like fenfluramine (the diet drug) and pergolide (a Parkinson’s treatment), were pulled from the market or restricted because they caused valvular heart disease. LSD shares structural similarities with these drugs, which raised an early alarm.²¹

A pharmacological analysis found that LSD and psilocybin can bind to the 5-HT2B receptor with potency equal to or greater than their binding at the 5-HT2A receptor, which is the primary target responsible for psychedelic effects. Safety margins relative to peak blood levels from typical microdoses were larger than those of known valve-damaging drugs, but the authors explicitly stated that the risk was not zero and concluded that valvular heart disease is a potential concern with chronic microdosing.²²

More recently, a mouse study directly tested this by giving animals microdose-level LSD chronically and comparing them to positive controls that received fenfluramine or serotonin. The fenfluramine group developed aortic valve problems as expected, but neither LSD dosing group showed any ventricular or valvular changes on echocardiography. The researchers noted that while LSD does produce meaningful 5-HT2B activation, it is brief compared to the sustained activation caused by fenfluramine.²³ This is reassuring but far from definitive. Mouse hearts are not human hearts, and the study periods involved are short relative to the years-long microdosing regimens some people follow. No clinical study has been specifically designed to evaluate heart valve risk in human microdosers.

The Problem With Illicit Doses

Most people who microdose are not receiving pharmaceutical-grade LSD. They are cutting blotter paper, diluting liquid drops, or relying on someone else’s estimate of the dose per tab. An analytical chemistry study that tested LSD microdosing samples obtained through a community drug-checking service found significant discrepancies between what users believed they were taking and the actual LSD content in their samples.²⁴ This matters because the difference between a dose that does essentially nothing, a dose that subtly alters mood, and a dose that produces unwanted perceptual disturbances can be just 10 or 15 micrograms. Inconsistent dosing also makes it nearly impossible to generalize from personal experience: someone who reports great results may be taking a meaningfully different amount from someone who reports nothing.

Degradation adds another layer of uncertainty. LSD is sensitive to light, heat, and moisture. Improperly stored liquid or blotter paper can lose potency over time in unpredictable ways, so even a batch that started at the intended concentration might drift. This is one of the reasons controlled trials matter so much in this area: without knowing the actual dose, individual reports of benefit or harm are almost impossible to interpret.

LSD Compared to Psilocybin at the Microdose Level

LSD and psilocybin are the two substances most commonly microdosed, and people often ask whether one is better suited to the practice. At full psychedelic doses, a head-to-head comparison found that the two drugs produced qualitatively and quantitatively very similar subjective effects, with any differences being dose-dependent rather than substance-dependent. The main distinction was duration: LSD’s effects last roughly twice as long.²⁵ At microdose levels, direct comparison data are scarce, but both substances share the same primary mechanism of action at the 5-HT2A receptor and both carry the same theoretical 5-HT2B cardiac concern. The practical differences that microdosers report, such as LSD feeling more energizing and psilocybin more calming, have not been confirmed in blinded laboratory settings.

Immune and Anti-Inflammatory Signals

A newer line of research is exploring whether psychedelics, including LSD, can modulate immune function. A review of the evidence found growing support for the idea that psychedelics can inhibit the release of pro-inflammatory signaling molecules, with animal studies showing reduced inflammation in models of asthma and other inflammatory conditions.²⁶ Most of this work has been done with other psychedelic compounds or at doses far above the microdose range, so direct applicability to LSD microdosing is speculative. But the serotonin receptors that LSD targets are present on immune cells, and researchers are interested in whether low-dose regimens could eventually have applications in chronic inflammatory disease. This is a field in its infancy rather than an established benefit.

Who Should Be Cautious

The clinical trials to date have generally found microdosing to be physically safe and psychologically well tolerated in screened, healthy volunteers. But clinical trials exclude the people who are most likely to run into problems. If you have a personal or family history of psychotic disorders like schizophrenia, any dose of a serotonergic psychedelic carries risk, because these drugs can trigger or worsen psychotic episodes. People taking lithium should avoid LSD entirely, as the combination has been associated with seizures in case reports. SSRIs and other serotonergic antidepressants create a more complicated picture: they can blunt LSD’s effects through receptor competition, but combining serotonergic drugs also theoretically raises the risk of serotonin syndrome, though documented cases at microdose levels are extremely rare.

The blood pressure increases, while modest, mean that people with uncontrolled hypertension or cardiovascular disease should think carefully before microdosing, especially on a repeated schedule. And the unresolved cardiac valve question means that anyone planning to microdose for months or years is essentially running an unmonitored experiment with unknown long-term cardiac consequences. The mouse data are reassuring, but the gap between a mouse study and a confident statement about human safety across years of chronic dosing is enormous.

For people not in any of these risk categories, the most likely downside of microdosing is spending time and money on something that may work no better than expecting it to work. That is not a trivial outcome if the alternative was seeking evidence-based treatment for a condition like depression or ADHD, but it is a different kind of risk from a physical safety hazard.